Spain's government and Farmaindustria renew pact

15 January 2018
spain-big

Farmaindustria, the Spanish pharma trade group, and the Ministries of Finance and Public Administration, and Health, Social Services and Equality, have signed the renewal of the Collaboration Agreement for 2018.

This accord was first agreed upon in December 2016 and continued from the Protocol signed back in November of 2015, the main objective of guaranteeing the public access to therapeutic innovations under equitable conditions and guaranteeing the sustainability of the National Health System.

The Agreement reconciles the rationalization of public expenditure from an efficiency and compliance point of view, with the commitments of the pharmaceutical industry providing the System with the best and most advanced resources available. In this sense, the renovation of the Agreement responds to the fulfillment of these objectives and to the climate of dialogue and collaboration that the Government and Farmaindustria have been maintaining throughout the last couple of years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical